Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery
Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American manufacturing, research, and development, creating high-tech jobs and expanding facilities.
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Executives mingled with North Carolina leaders in the city of Wilson to ceremonially break ground on Johnson & Johnson’s ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.
MedPage Today on MSN23h
FDA Expands Guselkumab Approval to Crohn's DiseaseThe FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.
Zacks Investment Research on MSN3d
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's DiseaseJohnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback